MM 45289, a potent glycopeptide antibiotic which interacts weakly with diacetyl-L-lysyl-D-alanyl-D-alanine

Area of Science:

• Microbiology
• Pharmacology
• Medicinal Chemistry

Background:

• Glycopeptide antibiotics, including vancomycin, are crucial for treating Gram-positive bacterial infections.
• MM 45289 (eremomycin) is a vancomycin-type antibiotic with demonstrated improved antibacterial potency.
• Understanding the precise mechanism of action and target interactions is vital for developing new antibiotics.

Purpose of the Study:

• To compare the antibacterial activity and target binding affinity of MM 45289 with vancomycin.
• To investigate the interaction of MM 45289 with its target site peptide mimetic, diacetyl-L-lysyl-D-alanyl-D-alanine (DALAA).
• To assess the implications of these findings for antibiotic mechanism studies and drug discovery.

Main Methods:

• Comparative analysis of antibacterial activity against relevant pathogens.
• Determination of binding affinity (Ka) of MM 45289 and vancomycin to DALAA.
• Quantification of DALAA concentrations required to reverse the antibacterial effects of both antibiotics.

Main Results:

• MM 45289 exhibits superior antibacterial activity compared to vancomycin.
• The binding affinity (Ka) of MM 45289 for DALAA is 23-fold lower than that of vancomycin.
• 10 to 50-fold higher concentrations of DALAA are required to counteract the activity of MM 45289 relative to vancomycin.

Conclusions:

• Despite enhanced antibacterial potency, MM 45289 has a weaker affinity for its target peptide mimetic.
• The observed differences in target interaction necessitate a re-evaluation of mode of action studies for glycopeptide antibiotics.
• These findings offer insights for developing novel mechanism-based screening strategies for new antibiotic candidates.